Breakthroughs in the field of multiple sclerosis have led to a better understanding of the
physiopathology of the disease, follow up, and treatment of the patients that develop …

Precision medicine in multiple sclerosis: biomarkers for dia... : Current Opinion in Neurology
Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment …

Objective Widespread implementation of cerebrospinal fluid (CSF) biomarkers of
Alzheimer's disease (AD) in clinical settings requires improved accuracy for diagnosis of …

Objective: To determine the prognostic value of selected biomarkers in clinically isolated
syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual. Methods …

Introduction Reliable cerebrospinal fluid (CSF) biomarkers enabling identification of
frontotemporal dementia (FTD) and its pathologic subtypes are lacking. Methods Unbiased …

Background and purpose The role of chitinases and chitinase‐like proteins in multiple
sclerosis (MS) is currently unknown; however, cerebrospinal fluid (CSF) levels of chitinase 3 …

The majority of patients presenting with a first clinical symptom suggestive of multiple
sclerosis (MS) do not fulfill the MRI criteria for dissemination in space and time according to …

Personalized medicine is the science of individualized prevention and therapy. In the last
decade, advances in high‐throughput approaches allowed the development of proteomic …

In the present study, CSF concentrations of NFL, t-tau, p-tau, GFAP, S-100B, YKL-40, MCP-
1, α-sAPP, β-sAPP, and Aβ38, Aβ40, Aβ42 were measured in 324 MS patients to test …

Background The cause of multiple sclerosis (MS) is currently unknown, but it is thought that
oxidative damage and iron metabolism mechanisms are involved. The aim of this study was …